| Zhou Yi |
Zhou Yi is currently the Chief Technical Officer at Adaptive Biotechnologies Corp. Prior to this, he obtained graduate degrees from the University of Missouri and Fudan University. |
| Chad Robins |
Chad Robins is the founder of Aortica Corp. (founded in 2014) where he holds the title of Director. He is also the founder of Adaptive Biotechnologies Corp. (founded in 2009) where he holds the title of Chairman & Chief Executive Officer. Mr. Robins currently holds the position of Director at Washington Biotechnology & Biomedical Association (since 2017). He also holds director positions at AdvaMedDx, HeadLight Technologies, Inc., and AltPep Corp.Mr. Robins has previously held the position of Independent Director at CM Life Sciences III, Inc. and Director at ARYA Sciences Acquisition Corp. II. Mr. Robins completed his undergraduate degree at Cornell University and holds an MBA from The Wharton School of the University of Pennsylvania. |
| Harlan Robins |
Harlan Robins is the founder of Adaptive Biotechnologies Corp. which was founded in 2009, where he holds the title of Chief Scientific Officer. He also held the title of Member at Fred Hutchinson Cancer Research Center from 2016 to 2019. Dr. Robins was an Independent Director at CM Life Sciences III, Inc. He received his undergraduate degree from Harvard University and his graduate and doctorate degrees from the University of California, Berkeley. |
| Francis Lo |
Francis Lo is currently the Chief People Officer at Adaptive Biotechnologies Corp. Prior to this, he worked as the Director of Global Talent Management at Starbucks Corp from 2015 to 2017. He also held a Vice President of Human Resources position at Whole Foods Market, Inc. Mr. Lo received his undergraduate degree from The University of Texas at Austin and his MBA from Stanford Graduate School of Business. |
| Sharon Benzeno |
Sharon Benzeno is currently the Chief Commercial Officer-Immune Medicine at Adaptive Biotechnologies Corp. Prior to this, she held the position of Senior Director at Elsevier, Inc. from 2013 to 2014. She also worked as a Senior Scientific Manager at AstraZeneca PLC from 2005 to 2011 and as a Senior Manager at Capgemini SE from 2011 to 2013. Dr. Benzeno completed her undergraduate degree at New York University, obtained an MBA from The Leonard N Stern School of Business, and earned a doctorate from New York University School of Medicine. |
| Kyle Piskel |
Mr. Kyle Piskel is a Chief Financial & Accounting Officer at Adaptive Biotechnologies Corp. He received his undergraduate degree from Eastern Washington University and a graduate degree from Gonzaga University. |
| Susan Bobulsky |
Susan Bobulsky is currently the Chief Commercial Officer at Adaptive Biotechnologies Corp. She holds an MBA from Stanford Graduate School of Business and an undergraduate degree from Stanford University. |
| Julie Rubinstein |
Julie Rubinstein is currently the Director at Gift of Life Biologics and a Trustee at The Valerie Fund. She also serves as the President & Chief Operating Officer at Adaptive Biotechnologies Corp. since 2011. Ms. Rubinstein has an undergraduate degree from The Wharton School of the University of Pennsylvania, an MBA from Harvard Business School, and another undergraduate degree from Annenberg School For Communication. |
| Michelle R. Griffin |
Michelle R. Griffin is an Independent Director at HTG Molecular Diagnostics, Inc. and Adaptive Biotechnologies Corp. She was formerly Chairman at Universal Cells, Inc., Director at Sonus Pharmaceuticals, Inc., Virginia Mason Medical Center, Opexa Therapeutics, Inc., PhaseRx, Inc., and Polynoma LLC. She was also Chief Financial Officer at Corixa Corp. and Chief Financial Officer & Senior Vice President at Dendreon Corp. & Emergent Product Development Seattle. She was Chief Operating Officer & Senior Vice President at Emergent Product Development Seattle and Chief Financial Officer & Executive Vice President at OncoGenex Pharmaceuticals, Inc. She is currently an Independent Director at Acer Therapeutics, Inc. and Chinook Therapeutics, Inc. She was also a Principal at Pacific Biotechnology Consulting Group. She received her undergraduate degree from George Mason University and her MBA from Seattle University. |
| Katey Owen |
Katey Owen is currently the Director at The End Fund. She is also serving as an Independent Director at Adaptive Biotechnologies Corp. since 2021. In addition, she has been the Director of Neglected Tropical Diseases at Bill & Melinda Gates Foundation Trust since 2017. Dr. Owen holds a doctorate degree from Purdue University. |
| Peter M. Neupert |
Mr. Peter M. Neupert is an Independent Director at Fortrea Holdings, Inc., a Lead Independent Director and Board Member at Adaptive Biotechnologies Corp. and an Independent Director at Laboratory Corp. of America Holdings. He is on the Board of Directors at Fortrea Holdings, Inc., Navigating Cancer, Inc., Adaptive Biotechnologies Corp., Clinithink Ltd., Laboratory Corp. of America Holdings, Kernel Labs Holding LLC, America Holdings, A California LP, Cranium, Inc., GlobalScholar Corp. and Vitalchat Inc. Mr. Neupert was previously employed as a Board Member by Truveta, Inc., a Board Member by higi SH LLC, a Board Member by Freedom Innovations LLC, an Operating Partner by Health Evolution Management Co. LLC, a Trustee by Fred Hutchinson Cancer Research Center, a Member by Institute of Medicine, a Board Member by aQuantive, Inc., a Chairman of BoD by drugstore.com, Inc., and a Vice President-Health Solutions Group by Microsoft Corp. He also served on the board at Quality Systems, Inc., aQuantive, Inc. and Foundation for the National Institutes of Health, Inc. He received his undergraduate degree from The Colorado College and an MBA from Tuck School of Business at Dartmouth. |
| Michael J. Pellini |
Mike is a Managing Partner of S32, a venture capital fund investing at the frontiers of technology and healthcare. Prior to joining S32 in 2017, he served as CEO of Foundation Medicine, a company which transformed the way pharmaceutical companies and physicians evaluate the genomic changes underlying a patient’s cancer, until he transitioned to Chairman through the close of Roche’s (RHHBY) acquisition of FMI in August 2018. Previously, he was President and COO of Clarient, a national leader in molecular pathology, which was acquired by GE Healthcare in 2010.
He currently serves as a member of the Board of Directors for Nusano, Singular Genomics (OMIC), Adaptive Biotechnologies (ADPT), Octave BioSciences, TwinStrand Genomics, the Personalized Medicine Coalition, and the American Cancer Society. He previously served on the board of Thrive Earlier Detection, which was acquired by Exact Sciences (EXACT) in 2021, and Tango Therapeutics (TNGX). Mike brings a breadth of understanding in personalized medicine, with a particular interest and focus on defeating cancer. He is also a member of the President’s Leadership Council at Thomas Jefferson University and Jefferson Health.
During the COVID pandemic, Mike served as a Senior Advisor to the Rockefeller Foundation’s efforts on COVID-19 testing.
Mike received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College. |
| Robert M. Hershberg |
Robert M. Hershberg was the founder of VentiRx Pharmaceuticals, Inc. founded in 2006, where he held the position of President, Chief Executive Officer & Director from 2012 to 2017. Currently, he holds multiple positions including Chairman, President & Chief Executive Officer at HilleVax, Inc. since 2020, Independent Director at Recursion Pharmaceuticals, Inc. since 2020, Independent Director at Fate Therapeutics, Inc. since 2020, and Independent Director at Adaptive Biotechnologies Corp. since 2013. He is also a Director at Cajal Neuroscience, Inc. and a Member at UW Medicine. He was also a Director at Guide Therapeutics, Inc. and held the position of Assistant Professor at Harvard Medical School. Dr. Hershberg has a doctorate degree from The Salk Institute for Biological Studies and undergraduate and doctorate degrees from the University of California, Los Angeles. |
